celecoxib has been researched along with carboplatin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Altorki, NK; Dannenberg, AJ; Ferrara, CA; Flieder, DB; Keresztes, RS; Korst, RJ; Libby, DM; Pasmantier, MW; Port, JL; Subbaramaiah, K; Yankelevitz, DF | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Kassam, A; Mandel, K | 1 |
| Carbone, DP; Choy, H; Csiki, I; Johnson, DH; Lu, B; Moretti, L; Morrow, JD; Mutter, R; Sandler, AB; Shyr, Y; Ye, F | 1 |
| D'Asta, M; Ferrandina, G; Fuoco, G; Legge, F; Paglia, A; Scambia, G | 1 |
| Christenson, R; Edelman, MJ; Hodgson, L; Jewell, S; Kratzke, R; Vokes, E; Wang, X | 1 |
| Biesma, B; Dalesio, O; Groen, HJ; Hiltermann, TJ; Hochstenbag, MM; Schramel, FM; Sietsma, H; Smit, HJ; Termeer, A; van den Berg, A; van den Borne, BE; van Putten, JW; Vincent, A | 1 |
| de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM | 1 |
| Bell, R; Khasraw, M | 1 |
| Dhanda, DS; Kompella, UB; Mirvish, SS; Tyagi, P | 1 |
| Gu, C; Shi, L; Yu, L; Zhong, D | 1 |
| Arts, H; de Munck, L; de Vries, E; Hollema, H; Hospers, G; Reyners, A; Timmer-Bosscha, H; van der Marel, P; van Kruchten, M | 1 |
| Booth, L; Carter, J; Dent, P; McGuire, WP; Poklepovic, A; Roberts, JL; Webb, T | 1 |
| Baggstrom, MQ; Bertino, E; Cheney, RT; Edelman, MJ; Friedman, PN; Gajra, A; Hahn, OM; Hodgson, L; Milne, G; Mitchell-Richards, K; Molina, J; Reckamp, KL; Ritter, J; Schiller, JH; Stinchcombe, TE; Thomas, SP; Vokes, EE; Wang, X | 1 |
| Agarwal, JP; Banavali, SD; Goud, S; Janu, A; Joshi, A; Kannan, S; Kumar, R; Mahajan, A; Menon, NS; More, S; Mummudi, N; Nakti, D; Noronha, V; Patil, VM; Pawar, A; Prabhash, K; Shah, S; Tibdewal, A; Yadav, A | 1 |
1 review(s) available for celecoxib and carboplatin
| Article | Year |
|---|---|
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
10 trial(s) available for celecoxib and carboplatin
| Article | Year |
|---|---|
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pneumonectomy; Preoperative Care; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2003 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prostaglandins; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2009 |
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Celecoxib; Endostatins; Female; Humans; Middle Aged; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrazoles; Quality of Life; Recurrence; Sulfonamides; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arachidonate 5-Lipoxygenase; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Quality of Life; Sulfonamides; Taxoids | 2011 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Taxoids | 2012 |
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Docetaxel; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Prognosis; Prospective Studies; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Tissue Array Analysis | 2015 |
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate | 2017 |
Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Celecoxib; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Methotrexate | 2022 |
4 other study(ies) available for celecoxib and carboplatin
| Article | Year |
|---|---|
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Celecoxib; Cisplatin; Disease Progression; Doxorubicin; Drug Therapy, Combination; Female; Hemangioendothelioma, Epithelioid; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Neovascularization, Pathologic; Pyrazoles; Radiography; Recombinant Proteins; Sulfonamides; Thalidomide; Vinblastine | 2008 |
Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzo(a)pyrene; Bronchoalveolar Lavage Fluid; Carboplatin; Celecoxib; Cell Count; Collagen; Delayed-Action Preparations; Female; L-Lactate Dehydrogenase; Lactic Acid; Lung Neoplasms; Mice; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Pulmonary Fibrosis; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2013 |
[Celecoxib antagonizes the cytotoxic effect of carboplatin in human esophageal cancer cells].
Topics: Apoptosis; Blotting, Western; Carboplatin; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Survival; Drug Interactions; Esophageal Neoplasms; Humans; Pyrazoles; Sulfonamides | 2014 |
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Topics: Antineoplastic Agents; Carboplatin; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Inhibitory Concentration 50; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Phenylurea Compounds; Sildenafil Citrate; Sorafenib | 2015 |